There are 360 resources available
89P - Durvalumab could be effective in combination with anti-HER2 agents in HER2-low breast cancer
Presenter: maryam arshad
Session: Poster Display
196TiP - A Phase 1 study of REGN6569, a GITR monoclonal antibody (mAb), in combination with cemiplimab in patients with advanced solid tumour malignancies
Presenter: Nehal Lakhani
Session: Poster Display
90P - Long-term outcomes in melanoma patients achieving a complete response under immune checkpoint inhibition
Presenter: Eftychia Chatziioannou
Session: Poster Display
197TiP - First-in-human (FIH) Phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)
Presenter: Kathleen Moore
Session: Poster Display
91P - Association between weight variation and survival in patients treated with immune checkpoint inhibitors
Presenter: Raquel Romao
Session: Poster Display
199TiP - A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES)
Presenter: Anthony Gonçalves
Session: Poster Display
93P - Cetuximab-based chemotherapy after progression on immune-checkpoint inhibitors in recurrent/metastatic head and neck squamous cell cancer
Presenter: Santiago Cabezas-Camarero
Session: Poster Display